252 related articles for article (PubMed ID: 12226074)
1. The "LSGGQ" motif in each nucleotide-binding domain of human P-glycoprotein is adjacent to the opposing walker A sequence.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2002 Nov; 277(44):41303-6. PubMed ID: 12226074
[TBL] [Abstract][Full Text] [Related]
2. Drug binding in human P-glycoprotein causes conformational changes in both nucleotide-binding domains.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2003 Jan; 278(3):1575-8. PubMed ID: 12421806
[TBL] [Abstract][Full Text] [Related]
3. Drug-stimulated ATPase activity of human P-glycoprotein is blocked by disulfide cross-linking between the nucleotide-binding sites.
Loo TW; Clarke DM
J Biol Chem; 2000 Jun; 275(26):19435-8. PubMed ID: 10806188
[TBL] [Abstract][Full Text] [Related]
4. Processing mutations located throughout the human multidrug resistance P-glycoprotein disrupt interactions between the nucleotide binding domains.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2004 Sep; 279(37):38395-401. PubMed ID: 15247215
[TBL] [Abstract][Full Text] [Related]
5. Nucleotide-induced conformational changes in P-glycoprotein and in nucleotide binding site mutants monitored by trypsin sensitivity.
Julien M; Gros P
Biochemistry; 2000 Apr; 39(15):4559-68. PubMed ID: 10758006
[TBL] [Abstract][Full Text] [Related]
6. Conserved Walker A cysteines 431 and 1074 in human P-glycoprotein are accessible to thiol-specific agents in the apo and ADP-vanadate trapped conformations.
Sim HM; Bhatnagar J; Chufan EE; Kapoor K; Ambudkar SV
Biochemistry; 2013 Oct; 52(41):7327-38. PubMed ID: 24053441
[TBL] [Abstract][Full Text] [Related]
7. The ATPase activity of the P-glycoprotein drug pump is highly activated when the N-terminal and central regions of the nucleotide-binding domains are linked closely together.
Loo TW; Bartlett MC; Detty MR; Clarke DM
J Biol Chem; 2012 Aug; 287(32):26806-16. PubMed ID: 22700974
[TBL] [Abstract][Full Text] [Related]
8. Function of the ABC signature sequences in the human multidrug resistance protein 1.
Ren XQ; Furukawa T; Haraguchi M; Sumizawa T; Aoki S; Kobayashi M; Akiyama S
Mol Pharmacol; 2004 Jun; 65(6):1536-42. PubMed ID: 15155846
[TBL] [Abstract][Full Text] [Related]
9. Both ATP sites of human P-glycoprotein are essential but not symmetric.
Hrycyna CA; Ramachandra M; Germann UA; Cheng PW; Pastan I; Gottesman MM
Biochemistry; 1999 Oct; 38(42):13887-99. PubMed ID: 10529234
[TBL] [Abstract][Full Text] [Related]
10. Nucleotide binding, ATP hydrolysis, and mutation of the catalytic carboxylates of human P-glycoprotein cause distinct conformational changes in the transmembrane segments.
Loo TW; Bartlett MC; Clarke DM
Biochemistry; 2007 Aug; 46(32):9328-36. PubMed ID: 17636884
[TBL] [Abstract][Full Text] [Related]
11. Purification and characterization of the N-terminal nucleotide binding domain of an ABC drug transporter of Candida albicans: uncommon cysteine 193 of Walker A is critical for ATP hydrolysis.
Jha S; Karnani N; Dhar SK; Mukhopadhayay K; Shukla S; Saini P; Mukhopadhayay G; Prasad R
Biochemistry; 2003 Sep; 42(36):10822-32. PubMed ID: 12962507
[TBL] [Abstract][Full Text] [Related]
12. The Walker B motif of the second nucleotide-binding domain (NBD2) of CFTR plays a key role in ATPase activity by the NBD1-NBD2 heterodimer.
Stratford FL; Ramjeesingh M; Cheung JC; Huan LJ; Bear CE
Biochem J; 2007 Jan; 401(2):581-6. PubMed ID: 16989640
[TBL] [Abstract][Full Text] [Related]
13. Cysteines introduced into extracellular loops 1 and 4 of human P-glycoprotein that are close only in the open conformation spontaneously form a disulfide bond that inhibits drug efflux and ATPase activity.
Loo TW; Clarke DM
J Biol Chem; 2014 Sep; 289(36):24749-58. PubMed ID: 25053414
[TBL] [Abstract][Full Text] [Related]
14. Disulfide cross-linking analysis shows that transmembrane segments 5 and 8 of human P-glycoprotein are close together on the cytoplasmic side of the membrane.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2004 Feb; 279(9):7692-7. PubMed ID: 14670948
[TBL] [Abstract][Full Text] [Related]
15. Val133 and Cys137 in transmembrane segment 2 are close to Arg935 and Gly939 in transmembrane segment 11 of human P-glycoprotein.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2004 Apr; 279(18):18232-8. PubMed ID: 14749322
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the functional characteristics of the nucleotide binding domains of multidrug resistance protein 1.
Gao M; Cui HR; Loe DW; Grant CE; Almquist KC; Cole SP; Deeley RG
J Biol Chem; 2000 Apr; 275(17):13098-108. PubMed ID: 10777615
[TBL] [Abstract][Full Text] [Related]
17. Processing mutations disrupt interactions between the nucleotide binding and transmembrane domains of P-glycoprotein and the cystic fibrosis transmembrane conductance regulator (CFTR).
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2008 Oct; 283(42):28190-7. PubMed ID: 18708637
[TBL] [Abstract][Full Text] [Related]
18. Cloning, overexpression, purification, and characterization of the carboxyl-terminal nucleotide binding domain of P-glycoprotein.
Sharma S; Rose DR
J Biol Chem; 1995 Jun; 270(23):14085-93. PubMed ID: 7775470
[TBL] [Abstract][Full Text] [Related]
19. Allosteric interactions between the two non-equivalent nucleotide binding domains of multidrug resistance protein MRP1.
Hou Y; Cui L; Riordan JR; Chang X
J Biol Chem; 2000 Jul; 275(27):20280-7. PubMed ID: 10781583
[TBL] [Abstract][Full Text] [Related]
20. Mutations in either nucleotide-binding site of P-glycoprotein (Mdr3) prevent vanadate trapping of nucleotide at both sites.
Urbatsch IL; Beaudet L; Carrier I; Gros P
Biochemistry; 1998 Mar; 37(13):4592-602. PubMed ID: 9521779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
